Cartilage matrix degradation enzymes

Cartilage matrix degradation enzymes represent a functional group of proteases responsible for the pathological breakdown of the extracellular matrix (ECM) in joint tissues. The group is primarily composed of matrix metalloproteinases (MMPs), such as MMP-13, which is the principal enzyme for type II collagen degradation, and A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) enzymes, particularly ADAMTS-4 and ADAMTS-5, which act as the major aggrecanases [1, 5, 10]. These enzymes are secreted by chondrocytes and synovial fibroblasts in response to mechanical stress and pro-inflammatory cytokines like interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) [4, 11, 19]. Their aberrant activity leads to the progressive loss of cartilage structural integrity, which is the hallmark of degenerative joint diseases. Therapeutic interventions aim to inhibit these enzymes to provide disease-modifying effects, although historical attempts with broad-spectrum inhibitors were limited by significant off-target toxicities [3, 8]. Current research focuses on highly selective small molecules and biologics, such as monoclonal antibodies and nanobodies, that target specific isoforms involved in disease progression while sparing those necessary for physiological tissue remodeling [7, 10, 13].

Other names

Cartilage-degrading proteasesExtracellular matrix-degrading enzymesMatrix metalloproteinases and aggrecanasesChondrocyte proteasesCollagenases and aggrecanases

Drugs targeting these enzymes typically act through competitive inhibition of the catalytic zinc-dependent active site, non-competitive binding to allosteric exosites to enhance selectivity, or monoclonal antibody-mediated neutralization of the enzyme surface. Newer approaches also include siRNA-mediated silencing of the mRNA encoding specific proteases such as MMP-13 or ADAMTS-5 to reduce their overall expression levels in the joint environment.